Lexicon Pharmaceuticals Stock Forecast, Price & News

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Lexicon Pharmaceuticals in the last twelve months. There are currently 6 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Lexicon Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in LXRX, but not buy additional shares or sell existing shares.
View analyst ratings for Lexicon Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Lexicon Pharmaceuticals a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Lexicon Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Lexicon Pharmaceuticals saw a drop in short interest in the month of March. As of March 31st, there was short interest totaling 3,730,000 shares, a drop of 24.0% from the March 15th total of 4,910,000 shares. Based on an average trading volume of 4,730,000 shares, the short-interest ratio is presently 0.8 days.
View Lexicon Pharmaceuticals' Short Interest.

Lexicon Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, April 26th 2021.
View our earnings forecast for Lexicon Pharmaceuticals.

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) announced its quarterly earnings results on Wednesday, March, 10th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.28) by $0.23. The biopharmaceutical company had revenue of $0.20 million for the quarter, compared to analysts' expectations of $0.17 million. Lexicon Pharmaceuticals had a negative trailing twelve-month return on equity of 164.96% and a negative net margin of 320.44%.
View Lexicon Pharmaceuticals' earnings history.

Lexicon Pharmaceuticals' stock was trading at $2.27 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, LXRX shares have increased by 128.6% and is now trading at $5.19.
View which stocks have been most impacted by COVID-19.

8 brokers have issued twelve-month target prices for Lexicon Pharmaceuticals' shares. Their forecasts range from $6.00 to $13.00. On average, they expect Lexicon Pharmaceuticals' stock price to reach $9.40 in the next twelve months. This suggests a possible upside of 81.1% from the stock's current price.
View analysts' price targets for Lexicon Pharmaceuticals or view top-rated stocks among Wall Street analysts.

9 employees have rated Lexicon Pharmaceuticals CEO Lonnel Coats on Glassdoor.com. Lonnel Coats has an approval rating of 100% among Lexicon Pharmaceuticals' employees. This puts Lonnel Coats in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Lexicon Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Exact Sciences (EXAS), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), Novavax (NVAX), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), United Therapeutics (UTHR) and Neurocrine Biosciences (NBIX).
View all of LXRX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Lexicon Pharmaceuticals investors own include Portola Pharmaceuticals (PTLA), Sarepta Therapeutics (SRPT), ACADIA Pharmaceuticals (ACAD), Dynavax Technologies (DVAX), MannKind (MNKD), ImmunoGen (IMGN), Geron (GERN), Micron Technology (MU), TherapeuticsMD (TXMD) and Gilead Sciences (GILD).

Lexicon Pharmaceuticals trades on the NASDAQ under the ticker symbol "LXRX."

Lexicon Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Boothe Investment Group Inc. (0.30%). Company insiders that own Lexicon Pharmaceuticals stock include Alexander A Santini, Christopher J Sobecki, James F Tessmer, Lonnel Coats and Sam L Barker.
View institutional ownership trends for Lexicon Pharmaceuticals.

LXRX stock was acquired by a variety of institutional investors in the last quarter, including Boothe Investment Group Inc.. Company insiders that have bought Lexicon Pharmaceuticals stock in the last two years include Alexander A Santini, Christopher J Sobecki, James F Tessmer, Lonnel Coats, and Sam L Barker.
View insider buying and selling activity for Lexicon Pharmaceuticals or or view top insider-buying stocks.

Shares of LXRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of LXRX stock can currently be purchased for approximately $5.19.

Lexicon Pharmaceuticals has a market capitalization of $749.20 million and generates $322.07 million in revenue each year. The biopharmaceutical company earns $130.13 million in net income (profit) each year or $1.35 on an earnings per share basis.

Lexicon Pharmaceuticals employs 78 workers across the globe.

The official website for Lexicon Pharmaceuticals is www.lexpharma.com.

Lexicon Pharmaceuticals is headquartered at 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX, 77381.

Lexicon Pharmaceuticals' mailing address is 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX, 77381. The biopharmaceutical company can be reached via phone at 281-863-3000 or via email at [email protected]